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Lower Macular Pigment Optical Density in
Foveal-Involved Glaucoma
We Fong Siah, MRCPI, FRCOphth,1 James Loughman, FAOI, PhD,2,3 Colm O’Brien, FRCOphth, MD1
Purpose: To evaluate the relationship between macular pigment optical density (MPOD) and structural
parameters of the macula and optic nerve head in glaucomatous eyes.
Design: A cross-sectional analysis of the baseline data collected during the Macular Pigment and Glaucoma
Trial (ISRCTN registry number: 56985060).
Participants: Eighty-eight subjects (48 male, 40 female) with a diagnosis of open-angle glaucoma and a
median age of 67 years (interquartile range, 13; range, 36e84 years) were enrolled in this trial.
Methods: The MPOD at 0.25 , 0.5 , and 1 retinal eccentricity was measured using a customized heterochromatic ﬂicker photometry technique. Glaucoma-related structural parameters were captured using RTVue
Fourier-domain optical coherence tomography (FD-OCT). Statistical signiﬁcance was set at P < 0.01, and P
values ranging from 0.01 to 0.05 were considered borderline signiﬁcant.
Main Outcome Measures: The MPOD and its relationship to the macula and optic nerve head topography in
glaucomatous eyes.
Results: The MPOD peaked centrally at 0.25 of retinal eccentricity (mean  standard deviation, 0.230.14)
and decreased at more peripheral eccentricities. For the overall group, borderline signiﬁcant correlations were
observed between MPOD and a range of topographic measures, including inferior peripapillary retinal nerve ﬁber
layer (RNFL) thickness, inferior ganglion cell complex (GCC) thickness, foveal inner retinal thickness, cup-to-disc
area ratio, and optic disc rim area. Glaucomatous eyes with GCC loss involving the foveal zone on FD-OCT
imaging (n ¼ 52) had lower MPOD at 0.25 , 0.5 , and 1 of retinal eccentricity compared with those without
foveal GCC involvement (P < 0.001, for all). Those with foveal GCC loss also had greater glaucoma severity, and
this was evident by lower GCC and RNFL thickness, greater cup-to-disc area ratio, and lower optic disc rim area
(P < 0.001 for all).
Conclusions: Our observations indicate that MPOD is lower in glaucomatous eyes with foveal GCC
involvement relative to those without foveal involvement. A longitudinal evaluation of MPOD and structural
change among patients with glaucoma is required to elucidate the nature of any causal relationship that might
exist between MPOD and foveal damage in glaucoma. Ophthalmology 2015;-:1e9 ª 2015 by the American
Academy of Ophthalmology.

The macula can be involved in the early stage of glaucoma, as
evidenced by the presence of paracentral scotoma on visual
ﬁeld tests1 or thinning of the ganglion cell complex (GCC)
layer on optical coherence tomography (OCT) scans.2 In the
human retina, the ganglion cells are most densely located at
the macula, and approximately 50% are concentrated within
4.5 mm of the fovea.3 Macular pigment (MP), which
comprises the hydroxycarotenoids lutein, zeaxanthin, and
meso-zeaxanthin, is also known to be most densely concentrated around the fovea.4 Both lutein and zeaxanthin are solely
of dietary origin, whereas meso-zeaxanthin can be synthesized
de novo from retinal lutein.5
Macular pigment is believed to possess the following
properties: (1) acts as a potent antioxidant,6 (2) exhibits
preferential spectral absorption of short-wavelength light,7
and (3) beneﬁts visual performance.8 Macular pigment
optical density (MPOD) in individual eyes can be measured
using a variety of techniques, including heterochromatic
ﬂicker photometry (HFP).9 The protective effect of MP has
 2015 by the American Academy of Ophthalmology
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been demonstrated in age-related macular degeneration
(AMD), a retinal neurodegenerative disorder in which old age
and oxidative stress have been implicated.10 It has been shown
that oral dietary MP supplementation can augment MPOD and
improve visual function in individuals with AMD11 and those
without underlying ocular disease.12
Glaucoma is also associated with the aging eye, and
oxidative stress is known to play a vital role in its pathogenesis.13 The possible role of oxidative stress in
glaucoma, coupled with emerging evidence that (1) the
structural integrity of the macula is affected early in
glaucoma and (2) MP levels may be compromised in
glaucoma14 was sufﬁcient to prompt this investigation
into the relationship between MP and structural aspects
of glaucoma in the macular region. To our knowledge,
this is the ﬁrst time the relationship between MPOD and
glaucoma-related topography has been investigated.
Given the fact that MP is largely concentrated to the central
1 of retinal eccentricity of the macula, we were keen to
http://dx.doi.org/10.1016/j.ophtha.2015.06.028
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explore glaucoma involving the foveal zone using OCT
imaging. Currently, the potential beneﬁt of dietary MP
supplementation in glaucoma is yet to be elucidated.

Methods
Subjects
The Macular Pigment and Glaucoma Trial is a prospective,
placebo-controlled, double-masked randomized study (ISRCTN
registry number: 56985060). This article comprises an analysis of
the baseline MP and structural data collected during this trial.
Eighty-eight subjects with a diagnosis of open-angle glaucoma
were recruited into this study, which has been approved by the
Research Ethics Committees at the Mater Misericordiae University
Hospital, Dublin, and the Dublin Institute of Technology. Written
informed consent was obtained from all subjects, and the study
adhered to the tenets of the Declaration of Helsinki.
Open-angle glaucoma was deﬁned as the presence of glaucomatous optic disc cupping with associated visual ﬁeld loss in an
eye with a gonioscopically open anterior chamber drainage angle.
The different open-angle glaucoma subtypes that were considered
for inclusion were (a) primary open-angle glaucoma (POAG)
(intraocular pressure >21 mmHg); (b) normal-tension glaucoma
(NTG) (intraocular pressure 21 mmHg); (c) pseudoexfoliative
glaucoma (ﬁbrillar deposits in the anterior segment of the eye);
and (d) pigment dispersion glaucoma (peripheral iris transillumination and pigment deposition throughout the anterior
segment structures of the eye). Other inclusion criteria were age
>18 years and subject capacity to adhere to trial protocol.
Exclusion criteria included an Early Treatment Diabetic Retinopathy Study (ETDRS) logarithm of the minimum angle of
resolution (logMAR) visual acuity >0.30, underlying ocular pathology such as AMD or moderate to signiﬁcant cataract (using
Lens Opacity Classiﬁcation System III grading), previous ocular
surgery other than for cataract extraction or glaucoma drainage
procedure, coexisting blue-light ﬁlter intraocular lens, history of
diabetes mellitus, or the use of an oral dietary macular pigment
supplement within the past 6 months. All subjects had characteristic and reproducible glaucomatous ﬁeld defects on standard
automated perimetry (Humphrey Visual Field [HVF] Analyzer
24-2 Swedish Interactive Threshold Algorithm Fast program;
Carl Zeiss Meditec, Jena, Germany).
Demographic information, including age, gender, type of glaucoma, years diagnosed with glaucoma, history of smoking (current
smoker, ex-smoker, and never smoked), and body mass index
(kilograms per meters squared) were recorded for each subject.
Throughout the study, only 1 eye per subject was selected for testing.
If both eyes were eligible, the study eye was randomly selected using
the randomization software Research Randomizer (version 4.0). All
glaucoma subjects underwent a comprehensive eye examination
including ETDRS logMAR visual acuity, slit-lamp biomicroscopy,
MPOD measurement (HFP), RTVue (software version 5.1; Optovue
Inc., Fremont, CA), Fourier-domain optical coherence tomography
(FD-OCT) imaging of the optic nerve head and macula, and standard
automated perimetry. The logMAR test chart used was computer
generated (version 1.1; KyberVision, Quebec, Canada), and visual
acuity was tested at a viewing distance of 4 m, using a Sloan ETDRS
letter set, while wearing current distance spectacle prescription where
required.

Measurement of Macular Pigment Optical Density
Heterochromatic ﬂicker photometry is a psychophysical technique for measuring MPOD that has been validated against the
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absorption spectrum of MP in vitro.15 It has also been shown to
provide reliable data when compared with other methods of
measuring MPOD, such as fundus reﬂectometry and
ﬂuorophotometry.16,17 Because the HFP technique is not dependent on or affected by regional variation in sensitivity at the
central and peripheral retinal loci (normal or disease-induced
variations),16 the HFP technique remains appropriate for MPOD
measurement among glaucoma subjects. In this study, MPOD
was measured using the Macular Densitometer (Macular
Metrics, Rehoboth, MA), a device originally described by Wooten
and colleagues.16 Subjects viewed a stimulus consisting of a square
wave, alternating blue (460 nm) and green (550 nm), ﬂickering
light-emitting diode light source. Subjects were required to make
iso-luminance matches, which were perceived as the point of cessation of ﬂicker (null ﬂicker). All subjects were shown a training video
before being tested with the densitometer and were afforded the
opportunity to practice the technique. A customized HFP approach
was used, a reﬁned technique that allowed the investigator to
predetermine the optimal ﬂicker frequency for each subject, thus
enabling a more discrete end point for the test and minimizing the
variance between readings.18 In this study, the spatial proﬁle of MP
at 0.25 , 0.5 , and 1 of retinal eccentricity was measured under
conditions of dimmed light at a viewing distance of 18.5 inches
(47 cm), with distance optical correction where required. Five
readings were obtained to produce a mean MPOD value at each
retinal eccentricity, which was deemed reliable and acceptable
for inclusion in the study when the standard deviation of
measures was 0.05 or less.

Fourier-Domain Optical Coherence Tomography
All subjects were scanned using the RTVue FD-OCT system, with
a scan speed of 26 000 A-scans/second and 5-mm axial resolution.
The protocols used included (a) the retinal nerve ﬁber layer
(RNFL) 3.45 scan; (b) the optic nerve head scan; (c) the Enhanced
Macular Map 5 (EMM5) scan; and (d) the GCC scan.
The RNFL 3.45 protocol acquired four 3.45-mm-diameter circular scans centered on the optic disc and provided the average
RNFL thickness at the temporal, superior, nasal, and inferior
quadrants (peripapillary RNFL). The optic nerve head scan pattern
consisted of 12 radial line scans of 3.4-mm length and 13
concentric rings (1.3- to 4.9-mm diameter) centered on the optic
disc, providing a detailed optic disc/rim/cup analysis. The EMM5
scan pattern captured 29 438 data points across the macula over
0.90 seconds and provided information such as the full retinal and
inner retinal thickness at the fovea, parafoveal, and perifoveal regions, which are 1 (w3.3 ), 3, and 5 mm in diameter, respectively.
The MP is localized within the foveal and parafoveal regions,
and therefore these regions were a priority focus in this study. The
EMM5 scan image was excluded from analysis in the presence of a
poor-quality image (signal strength <40), segmentation error, offcenter ﬁxation, or out-of-range image.19 The GCC scan pattern
speciﬁcally provided a comprehensive ganglion cell assessment
by measuring the thickness of the nerve ﬁber layer (ganglion cell
axons), ganglion cell layer (ganglion cell body), and inner
plexiform layer (ganglion cell dendrites) at the macula. The
macular region was scanned over 0.58 seconds and consists of 1
horizontal line and 15 vertical lines at 0.5-mm intervals. The
scan was centered 1 mm temporal to the fovea to produce a 7-mm2
region. The RTVue software cropped the outer 0.5-mm region to
provide a 6-mm GCC thickness map that was used for the calculation of the GCC Signiﬁcance Map. This 6  6-mm map spans an
area that is equivalent to the central 20 on a visual ﬁeld map. If the
signal strength index was poor at <40 or the scan was misaligned,
the images were not used.
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Figure 1. Ganglion cell complex (GCC) signiﬁcance map. A, Fovea-not-involved. B, Fovea-involved. N ¼ nasal; T ¼ temporal.

Ganglion Cell Complex Subgroups
In the GCC color-coded Signiﬁcance Map, the central, grey foveal
area (1.5 mm/5 diameter) covers the region where the GCC thickness is too thin to be evaluated. In a normal eye, the MP is most
densely located within the diameter of this grey area. Beyond
approximately 7 eccentricity, retinal MP becomes optically undetectable.20 Glaucoma subjects were divided into 2 subgroups based on
their GCC Signiﬁcance Map to better represent the GCC thickness in
relation to the anatomic location of the MP. All diagnostic parameters
in the GCC Signiﬁcance Map were color coded to indicate whether
there was any signiﬁcant GCC thickness reduction; P < 1% was
coded as red, P < 5% was coded as yellow, and P  5% was
coded as green. If the perimeter of the grey foveal area was green,
it was classiﬁed as “fovea-not-involved” (Fig 1A). If the red scale
encroached up to the grey area, it was classiﬁed as “foveainvolved” (Fig 1B). A general linear model analysis was used to
determine the effect of foveal involvement (“fovea-not-involved”
vs. “fovea-involved” subgroups) and age, years diagnosed with
glaucoma, smoking status, and body mass index on the dependent
variable, MPOD.

Dietary Intake of Lutein and Zeaxanthin
A self-administered, semiquantitative food frequency questionnaire
(Lutein Zeaxanthin Questionnaire) was used to assess the dietary
intake of lutein and zeaxanthin (Carotenoid & Health Laboratory,
Jean Mayer USDA Human Nutrition Center on Aging, Tufts
University, Medford, MA),21 as has been used in other MPOD
studies.22 This information allowed us to control for any MPOD
disparity that may arise from different dietary habits among the
glaucoma subjects.

Statistical Analysis
Results were analyzed using the statistical software package SPSS
(version 22.0; IBM Corp., New York, NY). The KolmogoroveSmirnov test (if n > 50) or ShapiroeWilk W test (if n  50) was
used to assess the normality of all variables before statistical analysis.
Most of the quantitative variables that were investigated exhibited a
normal distribution except for age, duration of glaucoma diagnosis,
body mass index, peripapillary RNFL thickness, superior macular
RNFL thickness, cup-to-disc ratio, and optic disc rim area. Various
statistical analyses including an independent t test, ManneWhitney U
test, analysis of variance (ANOVA) with post hoc tests, and Pearson
or Spearman correlation coefﬁcients were computed when

appropriate. A conservative 1% level of signiﬁcance was adopted
throughout the analysis to offset the risk of a type I error given the
multiple comparisons and correlations conducted, although the majority of statistical tests were unrelated. The GCC thickness subgroup
analyses (“fovea-not-involved” and “fovea-involved”) were performed to explore relationships, if any, with other glaucoma-related
OCT parameters and MPOD.

Results
Demographics
The demographics for all 88 glaucoma subjects are summarized in
Table 1. The right eye was selected for inclusion in 51 subjects
(58%), and the left eye was selected for the remaining 37
subjects (42%).

Macular Pigment Optical Density
Valid MPOD data were obtained for 69 subjects at 0.25 retinal
eccentricity (mean  standard deviation, 0.230.14), 81 subjects
at 0.5 eccentricity (0.190.12), and 59 subjects at 1 eccentricity
(0.120.09). Only 53 subjects had complete MPOD data at all 3
retinal eccentricities. Of these subjects, 46 displayed a typical MP
spatial proﬁle with a central peak at 0.25 and relative decline at
more peripheral eccentricities, whereas the remaining 7 subjects
exhibited atypical MP spatial proﬁles that peaked at 0.5 of retinal
eccentricity.
There was no statistically signiﬁcant correlation observed between MPOD and age (r ¼ 0.21, P ¼ 0.08 at 0.25 eccentricity;
r ¼ 0.23, P ¼ 0.04 at 0.5 eccentricity; r ¼ 0.17, P ¼ 0.19 at 1
eccentricity) or length of time since being diagnosed with glaucoma (r ¼ 0.24, P ¼ 0.05 at 0.25 eccentricity; r ¼ 0.09, P ¼
0.44 at 0.5 eccentricity; r ¼ 0.11, P ¼ 0.40 at 1 eccentricity),
although there was a trend toward signiﬁcance (P ¼ 0.01e0.05) in
both instances at some eccentricities. Likewise, no statistically
signiﬁcant correlation was observed between MPOD and body
mass index at any eccentricity (r ¼ 0.13, P ¼ 0.28 at 0.25 eccentricity; r ¼ 0.01, P ¼ 0.93 at 0.5 eccentricity; r ¼ 0.08, P ¼
0.57 at 1 eccentricity). Independent t test analysis showed no
gender-based difference in MPOD (P > 0.01 for all). One-way
ANOVA revealed no statistically signiﬁcant effect of smoking
habits (current smoker, ex-smoker, and never smoked) on MPOD.
Although there was no statistically signiﬁcant correlation between
MPOD and OCT structural parameters at the strict 0.01 threshold,
borderline signiﬁcant (P ¼ 0.01e0.05) correlations were observed
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Table 1. Subject Characteristics (N ¼ 88)
Characteristic

Result

Age (yrs), median (range)
Sex, n (%)
Male
Female
Study eye logMAR, mean  SD
Type of glaucoma, n (%)
POAG
NTG
PXG
PDG
Duration of glaucoma (yrs), median (range)
Smoking habits, n (%)
Never smoked
Ex-smoker
Current smoker
Body mass index (kg/m2), median (range)
Lutein intake (mg/dl), median (range)
Zeaxanthin intake (mg/dl), median (range)

67 (36e84)
48 (54.5)
40 (45.5)
0.030.10
45
31
9
3
6
42
36
10
25.5
0.7
0.1

(51.1)
(35.2)
(10.2)
(3.4)
(0.5e32)
(47.7)
(40.9)
(11.4)
(18.5e42)
(0e13.2)
(0e1.2)

for all). A general linear model analysis conﬁrmed a signiﬁcant effect
of foveal involvement (“fovea-not-involved” vs. “fovea-involved”
subgroups) on MPOD at all retinal eccentricities (P  0.001), but no
effect of age, years diagnosed with glaucoma, smoking status, and
body mass index on MPOD (P ¼ 0.12e0.72 at 0.25 retinal eccentricity, P ¼ 0.34e0.99 at 0.5 retinal eccentricity, P ¼ 0.49e0.88 at 1
retinal eccentricity).
Median lutein intake in the “fovea-not-involved” group was 0.7
mg/dl (range, 0e13.2 mg/dl), whereas that in the “fovea-involved”
group was 0.8 mg/dl (range, 0e13.1 mg/dl). These respective intakes were not statistically signiﬁcantly different (P ¼ 0.95, Manne
Whitney U test). Likewise, we did not ﬁnd any signiﬁcant difference
in zeaxanthin intake between the “fovea-not-involved” group (median, 0.1 mg/dl; range, 0e0.5 mg/dl) and the “fovea-involved”
group (median, 0.1 mg/dl, range, 0e1.2 mg/dl) (P ¼ 0.44, Manne
Whitney U test).

Discussion

between MPOD and a number of topographic measures, including
inferior peripapillary RNFL thickness, inferior GCC thickness,
inner retinal thickness at the fovea, cup-to-disc area ratio, and optic
disc rim area (Table 2).

Macular pigment has been shown to be lower among subjects with glaucoma compared with healthy controls.14 This
study extends those ﬁndings and suggests that a continuum
exists, whereby MPOD not only is lower in the presence of
glaucoma but also is further compromised in more severe
cases of the condition and, in particular, where foveal
ganglion cells are involved. We also found borderline
signiﬁcant correlations between MPOD in the overall
group and OCT-derived topography measures, which may
further imply a relationship between MP and glaucomarelated structural parameters.

Optical Coherence Tomography Parameters and
Ganglion Cell Complex Subgroups

Table 2. Relationship between Macular Pigment Optical Density
and Optical Coherence Tomography Parameters

LogMAR ¼ logarithm of the minimum angle of resolution; NTG ¼
normal-tension glaucoma; PDG ¼ pigment dispersion glaucoma; POAG ¼
primary open-angle glaucoma; PXG ¼ pseudoexfoliative glaucoma; SD ¼
standard deviation.

Of the 88 GCC scans completed, 3 demonstrated poor signal
strength and were eliminated from the analysis. In total, there were
33 subjects (38.8%) in the “fovea-not-involved” subgroup and 52
subjects (61.2%) in the “fovea-involved” subgroup.
Figure 2 shows the difference in MPOD spatial proﬁle between
the “fovea-not-involved” and “fovea-involved” subgroups. Table 3
shows the different types of glaucoma within the GCC subgroups
and other characteristics. The 2 most common types of glaucoma
within the “fovea-involved” group were POAG (n ¼ 22) and
NTG (n ¼ 23). Between these subgroups, no signiﬁcant
differences in MPOD or any OCT parameters were observed
(P > 0.01 for all).
Within GCC subgroups, no statistically signiﬁcant correlation
was observed between MPOD (at 0.25 , 0.5 , and 1 retinal eccentricities, respectively) and age, length of time since diagnosed
with glaucoma, and body mass index (P > 0.01 for all). There was
no signiﬁcant gender-based difference in MPOD at all retinal eccentricities within the GCC subgroups (P > 0.01 for all, independent t test). Furthermore, 1-way ANOVA did not reveal any
signiﬁcant effect of smoking habits on MPOD in either subgroup
(P > 0.01 for each).
A statistically signiﬁcant difference in MPOD between the “foveanot-involved” and “fovea-involved” GCC subgroups was observed at
all retinal eccentricities (P < 0.001 for all) (Table 4). Furthermore, the
“fovea-involved” group exhibited more severe glaucoma as
determined by thinner RNFL and GCC, larger cup-to-disc area ratio,
and a smaller optic disc rim area (P < 0.01 for each). However, MPOD
did not correlate signiﬁcantly with OCT structural parameters for the
“fovea-not-involved” or “fovea-involved” GCC subgroup (P > 0.01
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MPOD 0.25 MPOD 0.5
R*
Peripapillary RNFL thickness
Average
0.15y
Superior
0.13y
Inferior
0.21y
Macular RNFL thickness
Average
0.11
Superior
0.05y
Inferior
0.18
GCC thickness
Average
0.15
Superior
0.06
Inferior
0.21
Foveal thickness
Full retina
0.09
Inner retina
0.19
Parafoveal thickness
Full retina
0.03
Inner retina
0.16
Cup-to-disc-area ratio
0.27y
Optic disc rim area
0.28y

P

R*

P

MPOD 1
R*

P

0.23
0.31
0.09

0.16y 0.18
0.12y 0.30
0.23y 0.05

0.07y 0.60
0.02y 0.89
0.15y 0.28

0.36
0.68
0.14

0.18 0.12
0.11y 0.35
0.21 0.07

0.12 0.36
0.03y 0.83
0.16 0.22

0.24
0.63
0.09

0.16 0.15
0.11 0.33
0.18 0.11

0.22 0.09
0.13 0.33
0.27 0.04

0.52
0.17

0.18 0.15
0.29 0.02

0.18 0.22
0.23 0.11

0.85
0.09 0.46 0.07 0.66
0.24
0.20 0.11 0.14 0.35
0.03 0.25y 0.03 0.28y 0.04
0.02
0.22y 0.06 0.22y 0.10

GCC ¼ ganglion cell complex; MPOD ¼ macular pigment optical density;
RNFL ¼ retinal nerve ﬁber layer.
P ¼ signiﬁcance (2-tailed).
*Pearson coefﬁcient correlation (unless indicated otherwise).
y
Spearman coefﬁcient correlation.
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Figure 2. Mean macular pigment optical density (MPOD) spatial proﬁle
for subjects with glaucoma.
, Fovea-Not-Involved;
, FoveaInvolved.

In this study, only half of the patients with POAG had foveal
involvement compared with a large proportion of those with
NTG (77%). This ﬁnding was not surprising to us given that
paracentral scotoma is a common ﬁnding in the early course of
NTG. Pseudoexfoliative glaucoma is generally recognized as a
more progressive glaucoma subtype. This may explain why the
majority (78%) of patients in the pseudoexfoliative glaucoma
group had foveal-involved glaucoma and displayed the worst
glaucoma parameters (HVF 24-2 mean deviation [MD] and
average GCC thickness, respectively) compared with other
glaucoma subtypes.
Beatty et al23 previously demonstrated the ﬁnding of an agerelated decline in MPOD in individuals with healthy eyes,
whereas an earlier study by Bone et al20 showed the contrary.
Given that glaucoma is a progressive retinal degenerative
disease that tends to affect the aging individual, one could
speculate that increasing age may, in part, be contributing to
the decline in MPOD with advancing disease. Although
subjects in the “fovea-involved” subgroup were older than in

the “fovea-not-involved” subgroup (mean age, 67.9 vs. 62.6
years, respectively), this difference was only borderline
signiﬁcant (P ¼ 0.02, independent t test). However, our data
are in keeping with the ﬁndings of Bone et al20 and do not
support the existence of a relationship between MPOD and
age. Our earlier study (Igras et al14) showed that MPOD was
signiﬁcantly lower in glaucomatous eyes compared with agematched controls. With our current data, it would seem that
age is not a confounding factor, but the presence of foveal GCC
loss is a major determinant of MPOD levels.
Adipose tissue acts as a major storage organ for carotenoids and therefore may compete with the retina for their
uptake. It has been shown that an inverse relationship exists
between MPOD and body mass index in those with healthy
eyes.24 In our study, we did not ﬁnd any correlation between
MPOD and body mass index.
In human eyes, the most central part of the fovea (also known
as the foveal pit) measures 200 mm in diameter and is a region
where only cone photoreceptors can be found.3 From here, the
inner retinal structures are displaced radially to form the foveal
slope, and eventually, at the parafovea (thickest portion of the
retina), the ganglion cells are packed 6 layers thick. Macular
pigment can be localized to the ﬁbers of Henle and plexiform
layers at the fovea and the inner and outer plexiform layers at
the parafovea.4 This is of relevance because the 3 innermost
retinal layers preferentially affected in glaucoma are (1) nerve
ﬁber layer (ganglion cell axon), (2) ganglion cell layer
(ganglion cell body), and (3) inner plexiform layer (ganglion
cell dendrites).25 Collectively, these 3 retinal layers constitute
the GCC as measured by the RTVue FD-OCT.
Because of limitations of the RTVue FD-OCT to reliably
evaluate GCC thickness at the fovea, we described a simple
method to allow us to distinguish the presence or absence of
foveal involvement in glaucoma subjects (see “Methods”
section). The MPOD was signiﬁcantly lower in subjects
who exhibited evidence of GCC thinning that encroached
on the foveal zone (“fovea-involved” GCC) relative to
those without foveal GCC involvement. Given that the
macular layers where MP is housed appear to be affected
by glaucoma, this may explain, at least in part, the
observation in this study that MPOD is lower in
individuals with more severe glaucoma and, in particular,
those with GCC loss at the fovea. However, our data in
this study are not sufﬁcient enough to make any
conclusions on causal inferences.

Table 3. Types of Glaucoma and Characteristics
Fovea-Not-Involved (n [ 33)
Types of Glaucoma
POAG
NTG
PXG
PDG

n (%)
22
7
2
2

(50)
(23)
(22)
(100)

HVF 24-2 MD (dB)*
y

5.72
5.30
9.68
4.50

Fovea-Involved (n [ 52)

Mean GCC (mm)
77.31
83.85
75.90
74.83

n (%)
22
23
7
0

(50)
(77)
(78)
(0)

HVF 24-2 MD (dB)*
y

10.41
8.79
16.24
N/A

Mean GCC (mm)
70.11
71.47
68.66
N/A

dB ¼ decibels; GCC ¼ ganglion cell complex; HVF ¼ Humphrey Visual Field; MD ¼ mean deviation; N/A ¼ not applicable; NTG ¼ normal-tension
glaucoma; PDG ¼ pigment dispersion glaucoma; POAG ¼ primary open-angle glaucoma; PXG ¼ pseudoexfoliative glaucoma.
*Mean (unless indicated otherwise).
y
Median.
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Table 4. Comparison between Ganglion Cell Complex Subgroups

MPOD, mean  SD
0.25
0.50
1.00
RNFL thickness (mm), mean  SD
Peripapillary
Macular
GCC thickness (mm), mean  SD
Foveal thickness (mm), mean  SD
Full fovea
Inner fovea
Outer fovea
Parafoveal thickness (mm), mean  SD
Full parafovea
Inner parafovea
Cup-to-disc area ratio, median (range)
Rim area (mm2), median (range)
HVF 24-2 MD (dB), median (range)

Fovea-Not-Involved

Fovea-Involved

P Value

0.300.12
0.240.12
0.170.07

0.170.11
0.150.10
0.080.08

<0.001*
<0.001*
<0.001*

77.589.80
79.6612.55
78.467.71

69.338.34
69.7010.65
70.389.34

<0.001*
<0.001*
<0.001*

270.0019.55
86.5411.93
183.4611.19

253.0223.08
76.7614.84
176.2611.91

0.002*
0.005*
0.013*

306.0320.06
119.0612.25
0.76 (0.36e0.97)
0.43 (0.06e0.86)
5.46 (1.45 to 26.46)

285.4518.99
106.209.42
0.88 (0.55e0.98)
0.22 (0.05e0.71)
10.54 (0.09 to 31.06)

<0.001*
<0.001*
<0.001y
<0.001y
0.018y

dB ¼ decibels; GCC ¼ ganglion cell complex; HVF ¼ Humphrey visual ﬁeld; MD ¼ mean deviation; MPOD ¼ macular pigment optical density; RNFL ¼
retinal nerve ﬁber layer; SD ¼ standard deviation.
*Two-tailed signiﬁcance using the independent t test.
y
Two-tailed signiﬁcance using the ManneWhitney U test.

In our earlier study, we showed that MPOD was signiﬁcantly lower in glaucomatous eyes compared with controls.14
Also using the HFP technique, Igras et al14 showed that mean
MPOD  standard deviation was 0.390.24 in a similar
cohort of normal controls, in comparison with 0.190.12 at
0.5 of retinal eccentricity in this study. The current study
was not designed to repeat that investigation, but rather to
extend the study in an effort to better understand the
relationship between MPOD and glaucoma-related structural
parameters. As such, the lack of a normal control group is not a
substantial limitation to the current study.
Igras et al14 also reported that MPOD did not correlate
with glaucoma severity (HVF 24-2 MD), whereas the
present study demonstrated a borderline signiﬁcant (P ¼
0.01e0.05) correlation between MPOD and glaucomarelated structural parameters as measured by RTVue FDOCT in the overall group. Furthermore, we also found that
those with foveal-involved glaucoma had more severe disease
(OCT parameters, P < 0.01; HVF 24-2 MD, P ¼ 0.02) and
demonstrated lower MPOD (P < 0.001) compared with those
without foveal involvement. This disparity between the 2
studies likely reﬂects limitations in our earlier study, which
had a smaller sample size (and therefore lacked statistical
power), and where, importantly, a central visual ﬁeld test
(HVF 10-2) and OCT scans to capture foveal loss were not
used. The majority of the subjects in this study had fovealinvolved glaucoma, whereas this information was not available for analysis during our earlier study. Therefore, the
differences in results between the studies do not suggest a
contradiction, but rather emphasize the differences in the
study methodology.
We also observed that a small subset of our glaucoma
subjects (7/53 subjects [13%] with complete MPOD data at
all eccentricities) exhibited an atypical MP spatial proﬁle,
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which peaked at 0.50 of retinal eccentricity. Six of these 7
subjects had foveal-involved glaucoma. In a study of
healthy subjects, Kirby et al26 found that atypical MP spatial
proﬁle was related to the foveal slope such that the steeper
the foveal depression, the steeper the MP distribution. The
signiﬁcance of an atypical MP spatial proﬁle in glaucoma
is currently unknown, and therefore further studies are
warranted to better understand it.
In this study, both the full parafoveal (P < 0.001) and foveal
thickness (P ¼ 0.002) were signiﬁcantly lower in the “fovea
involved” group, which exhibited greater glaucoma severity. In
a study of patients with POAG with isolated superior or inferior
hemiﬁeld defects, it was shown that the retinal thickness at the
parafovea and fovea linearly correlated with glaucoma
severity.27 Furthermore, Inuzuka et al27 also showed that the
parafoveal and foveal thicknesses were signiﬁcantly reduced
in the corresponding hemiﬁeld defects when compared with
the normal side. Another study demonstrated the ﬁnding of a
thin parafoveal ring on time-domain OCT imaging in subjects
with more advanced glaucoma but not for full foveal thickness.28 This discrepancy in ﬁndings may be related to the use of
different OCT imaging modalities across the studies; for
example, time-domain OCT has been shown to exhibit a
higher percentage of clinically signiﬁcant inaccurate central
foveal thickness compared with FD-OCT.19
A statistically signiﬁcantly reduced outer foveal thickness
was observed in the “fovea-involved” group (P ¼ 0.01). This
ﬁnding suggests that cone photoreceptors may be affected in
foveal-involved glaucoma. A histologic study of human eyes
with a diagnosis of chronic glaucoma demonstrated cone
photoreceptor swelling and loss.29 Furthermore, fundus
reﬂectometry and OCT imaging techniques have provided
evidence of the loss of foveal cone outer segment integrity
in subjects with POAG with advanced central visual ﬁeld
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defects,28 while loss of cone density in glaucomatous eyes
has been shown to correspond with retinal locations of
greater visual sensitivity loss.30 Although this study does
not provide deﬁnitive evidence of cone photoreceptor loss,
the observed involvement of those structures where MP is
housed, including signiﬁcantly thinner parafovea and inner
fovea, and a borderline signiﬁcantly thinner outer fovea,
may provide some explanation as to our ﬁnding of lower
MPOD in foveal-involved glaucoma.
The macula is susceptible to oxidative injury because it is
highly aerobic, constantly exposed to light (ultraviolet A and
short-wavelength blue light are particularly hazardous), and
environmental chemicals such as cigarette smoke.31
Furthermore, the presence of high levels of polyunsaturated
fatty acids predisposes to the generation of reactive oxygen
species. Retinal ganglion cells (RGCs) are highly
dependent on mitochondria for energy and are particularly
vulnerable to oxidative stress.32 The ﬁnding of lipofuscin
accumulation in glaucomatous eyes emphasizes the
importance of oxidative stress in glaucoma pathogenesis.33
Ghanem et al34 studied the levels of malondialdehyde, an
antioxidant enzyme, in aqueous humor samples of patients
with POAG (n ¼ 30) and found that it was signiﬁcantly
correlated with visual ﬁeld loss (P < 0.001), indicating that
increased oxidative stress is associated with more glaucoma
damage.34 Lutein35 and zeaxanthin36 have been shown to
confer a protective effect against oxidative stresseinduced
cell damage in in vitro studies using the RGC-5 cell line.
Likewise, lutein has been shown to increase the survival of
RGCs by decreasing oxidative stress in a model of acute
retinal ischemiaereperfusion in mice.37 We postulate that an
environment of high oxidative stress such as glaucoma can
cause MP to be depleted, and thereby potentially explain
the ﬁnding of lower MPOD in glaucomatous eyes
exhibiting foveal involvement and more severe damage.

Study Limitations
We were not able to obtain complete MPOD data at all 3
retinal eccentricities in some glaucoma subjects because
they found the HFP task somewhat difﬁcult to perform and
time-consuming with consequent fatigue. Because the HFP
technique is a psychophysical test, it is observer-dependent
and may explain the difﬁculty in carrying out the task.
Furthermore, the presence of glaucoma may have contributed to additional challenges. Despite that, HFP is still
considered a reliable and practical method to measure
MPOD.16 However, it may be worthwhile to incorporate a
less onerous and time-consuming imaging test such as
fundus autoﬂuorescence in future studies.17,38
Currently, an imaging system that can accurately measure the GCC thickness at the fovea is lacking. The Cirrus
HD-OCT (Carl Zeiss Meditec, Dublin, CA) uses the Ganglion Cell Analysis protocol to measure 2 retinal layers at
the macula, namely, the ganglion cell and inner plexiform
layers, unlike the RTVue FD-OCT that measures 3 layers
including the nerve ﬁber.39 In the context of studying MP,
Cirrus HD-OCT may have a slight advantage over the
RTVue FD-OCT because its macular area of analysis is
centered on the fovea, compared with 1 mm temporal to the

fovea in the latter. Nevertheless, both OCT devices are not
capable of reliably measuring the ganglion cell layer at the
fovea. Our method of determining whether GCC loss affects
the foveal region by referring to the GCC Signiﬁcance Map
of the RTVue FD-OCT remained effective in providing us
with sufﬁcient data for analysis in this study.
Given the limitations of this study, we can only postulate as to the likely explanation for the ﬁnding that MPOD
is lower in foveal-involved glaucoma. First, as discussed
earlier, it may be possible that when the foveal and parafoveal structures are affected in glaucoma, loss of the MP
housing initiates MPOD depletion. Second, low levels of
MPOD, due to poor dietary intake or impaired carotenoid
absorption, metabolism, and transportation, may predispose RGC to oxidative damage because of the lack of its
protective antioxidant effect, leading to eventual foveal
damage. Third, given that the macula is a highly aerobic
tissue and that glaucoma creates an environment of chronic
oxidative stress, MP may be constantly used up to scavenge free radicals, leading to MPOD depletion. This may
be especially evident in those with foveal-involved glaucoma, in whom the RGCs are under immense oxidative
stress and MP storage depletes faster than it can be
replenished. Therefore, augmentation of MPOD by dietary
modiﬁcation or supplementation may be desirable in patients with glaucoma, particularly those with evidence of
foveal involvement. However, the potential protective role
of oral MP supplementation against foveal damage in
glaucoma remains to be elucidated.
In this study, we investigated the relationship between
MP and macula and optic nerve head topography in glaucoma. Our study complements previous ﬁndings that
glaucoma is associated with lower MPOD levels and extends the relationship such that MPOD, it seems, is lower in
more severe cases of glaucoma exhibiting foveal involvement. Further research is merited to better deﬁne the
causative roles of oxidative stress, impaired ocular blood
ﬂow, and other factors that might inﬂuence MP levels in
glaucoma. In addition, it is important to evaluate whether
oral dietary MP supplementation in patients with glaucoma
can (1) increase MPOD and (2) affect glaucoma-related
structural parameters.
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